The four patients with partial responses included one patient with alveolar soft part sarcoma treated with an anti-VEGF agent, one with malignant fibrous histiocytoma treated with a combination of inhibitors of VEGF and histone deacetylase (HDAC), one with chondrosarcoma treated with a TRAIL (TNF-related apoptosis-inducing ligand) agent, and one patient with lymphangiomyomatosis treated with a combination of VEGF and mTOR inhibitors. Here, HDAC9 is linked to lymphangioleiomyomatosis.